PMID: 18210824Jan 24, 2008Paper

Treatment of seronegative myasthenia garvis

Rinshō shinkeigaku = Clinical neurology
Masakatsu Motomura

Abstract

Myasthenia gravis (MG) is an antibody-mediated autoimmune disease of the neuromuscular junction. It is classified into 1) the nicotinic acetylcholine receptor antibodies (80-85%), 2) muscle- specific tyrosine kinase antibodies (5-10%), and 3) the above-mentioned antibody absent, double seronegative MG. In this symposium, I focused the treatment of double seronegative MG.

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.